PFE, has entered a global licensing agreement with Novavax to use Matrix-M adjuvant technology in the development of up to ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Pfizer CEO Albert Bourla called vaccine skepticism in the highest levels of the federal government “an anomaly” during an investor call on Tuesday. “We will continue investing in vaccines because, as ...